CM
EGRX

Castleark Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Castleark Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-116,520
Closed -$9.24M – 417
2016
Q4 		$9.24M Buy
+116,520
New +$8.46M 0.29% 114
2016
Q1 		– Sell
-133,410
Closed -$11.8M – 422
2015
Q4 		$11.8M Buy
+133,410
New +$10.5M 0.36% 73

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Castleark Management's EGRX Position: Q1 2017 in Review

Castleark Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2017, closing a stake of 116,520 shares — an estimated $9.24M sold.

Castleark Management first reported a position in EGRX in Q4 2015 and held it in 2 quarters. The position peaked at $11.8M in Q4 2015. 147 funds tracked by Wall St. Rank hold EGRX as of Q1 2017.

  • Castleark Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Castleark Management sold 116,520 Eagle Pharmaceuticals, Inc. shares in Q1 2017, an estimated $9.24M.
  • Castleark Management first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2015 and held it in 2 quarters.
  • Castleark Management's Eagle Pharmaceuticals, Inc. position peaked at $11.8M in Q4 2015.
  • 147 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2017.

Based on Castleark Management's 13F filing for Q1 2017, filed 15 May 2017.